Home > Insider Trading > Filing (0001209191-18-048664)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1446847	Ironwood Pharmaceuticals Inc	IRWD	Pharmaceutical Preparations (2834)	043404176

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1478244	G Mark Currie	C/O Ironwood Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class B Common Stock	Acquisiton	2018-08-24	16,667	$4.89	791,667	No	4	M	Direct
Class B Common Stock	Acquisiton	2018-08-24	41,667	$4.89	833,334	No	4	M	Direct
Class B Common Stock	Acquisiton	2018-08-24	6,666	$5.48	840,000	No	4	M	Direct
Class B Common Stock	Disposition	2018-08-24	65,000	$18.39	775,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class B Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-08-24	16,667	$0.00	16,667	$4.89
Class B Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-08-24	41,667	$0.00	41,667	$4.89
Class B Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-08-24	6,666	$0.00	6,666	$5.48

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2019-02-11	No	4	M	Direct
0	2019-02-11	No	4	M	Direct
20,000	2019-07-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	30,124	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.21 to $18.65, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option was fully vested as of its grant date of February 12, 2009.
The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013.
The option vests in two equal installments based on the issuer's achievement of certain regulatory and commercial milestones. Upon achievement of a regulatory milestone, the option vested as to 20,000 shares of Class B Common Stock on January 4, 2017.